These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 16424543)

  • 1. Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion.
    Lai TY; Lee GK; Chan WM; Lam DS
    Br J Ophthalmol; 2006 Feb; 90(2):243-4. PubMed ID: 16424543
    [No Abstract]   [Full Text] [Related]  

  • 2. Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine.
    Viola F; Barteselli G; Dell'arti L; Vezzola D; Villani E; Mapelli C; Zanaboni L; Cappellini MD; Ratiglia R
    Ophthalmology; 2012 Aug; 119(8):1693-700. PubMed ID: 22480740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and therapeutic challenges.
    Reddy S; Slakter J; Aaberg TM; Singh RP; Kaiser PK
    Retina; 2007 Jun; 27(5):642-7. PubMed ID: 17558329
    [No Abstract]   [Full Text] [Related]  

  • 4. [Retinopathy caused by desferrioxamine].
    Sánchez Dalmau BF; Vela Payán MD
    Med Clin (Barc); 1996 Nov; 107(16):636. PubMed ID: 9064398
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of desferoxamine on retinal and visual function.
    Lu M; Hansen RM; Cunningham MJ; Eklund SE; Fulton AB
    Arch Ophthalmol; 2007 Nov; 125(11):1581-2. PubMed ID: 17998528
    [No Abstract]   [Full Text] [Related]  

  • 6. Macular vitelliform lesion in desferrioxamine-related retinopathy.
    Genead MA; Fishman GA; Anastasakis A; Lindeman M
    Doc Ophthalmol; 2010 Oct; 121(2):161-6. PubMed ID: 20532952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal imaging in a case of deferoxamine-induced maculopathy.
    Gelman R; Kiss S; Tsang SH
    Retin Cases Brief Rep; 2014; 8(4):306-9. PubMed ID: 25372534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population.
    Baath JS; Lam WC; Kirby M; Chun A
    Retina; 2008 Jun; 28(6):894-9. PubMed ID: 18536609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ocular side effects of deferoxamine therapy in aplastic anemia with transfusion-induced hemochromatosis].
    Spraul CW; Schicketanz C; Lang GE
    Klin Monbl Augenheilkd; 1996 Jul; 209(1):31-6. PubMed ID: 8965474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marrow proliferation as a cause of hearing loss in beta-thalassaemia major.
    Thio D; Prasad V; Anslow P; Lennox P
    J Laryngol Otol; 2008 Nov; 122(11):1253-6. PubMed ID: 17931455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Retinal pigment epithelium--desferal].
    Roulez F
    Bull Soc Belge Ophtalmol; 2007; (304):59-66. PubMed ID: 17718228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desferrioxamine-related ocular toxicity: a case report.
    Simon S; Athanasiov PA; Jain R; Raymond G; Gilhotra JS
    Indian J Ophthalmol; 2012 Jul; 60(4):315-7. PubMed ID: 22824603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment.
    Levine JE; Cohen A; MacQueen M; Martin M; Giardina PJ
    J Pediatr Hematol Oncol; 1997; 19(2):139-41. PubMed ID: 9149744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe infections in thalassaemic patients: prevalence and predisposing factors.
    Rahav G; Volach V; Shapiro M; Rund D; Rachmilewitz EA; Goldfarb A
    Br J Haematol; 2006 Jun; 133(6):667-74. PubMed ID: 16704445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful desensitization of a case with desferrioxamine hypersensitivity.
    Gülen F; Demir E; Tanaç R; Aydinok Y; Gulen H; Yenigün A; Can D
    Minerva Pediatr; 2006 Dec; 58(6):571-4. PubMed ID: 17093379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature.
    Tam DH; Farber HW
    Am J Hematol; 2006 Jun; 81(6):443-7. PubMed ID: 16680745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
    Shamsian BS; Aminasnafi A; Moghadassian H; Gachkar L; Arzanian MT; Alavi S; Esfehani H; Garallahi F; Amini R
    Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and management of pediatric patients with anaphylactoid reactions to deferoxamine mesylate.
    Somech R; Seaban-Adel K; Atkinson A; Kirby-Allen M
    Ann Allergy Asthma Immunol; 2007 Dec; 99(6):575-6. PubMed ID: 18219844
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute kidney injury due to deferoxamine in a renal transplant patient.
    Clajus C; Becker JU; Stichtenoth DO; Wortmann J; Schwarz A; Kielstein JT
    Nephrol Dial Transplant; 2008 Mar; 23(3):1061-4. PubMed ID: 18039640
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.